PURPOSE: T-cell depletion (TCD) reduces the incidence of graft-versus-host disease (GVHD) after hematopoietic cell transplantation (HCT). However, concerns about relapse, graft rejection, and variability in technique have limited the widespread application of this approach. PATIENTS AND METHODS: Outcomes of 44 patients receiving HLA-identical sibling TCD grafts using a uniform technique for CD34(+) selection as the sole form of immune suppression were compared with outcomes of 84 patients receiving T-replete grafts and pharmacologic immune suppression therapy (IST). RESULTS: Groups were similar, except for fewer men (36% with TCD v 56% with IST) and more frequent use of radiation-containing regimens (100% with TCD v 50% with IST) in the CD34-selected TCD cohort. The proportion of patients with neutrophil engraftment at day 28 was similar (96% with IST and 100% with TCD grafts). The 100-day rates of grade 2 to 4 acute GVHD were 39% and 23% with IST and TCD grafts, respectively (P = .07). Corresponding 2-year rates of chronic GVHD were lower with TCD grafts than IST (19% v 50%, respectively; P < .001). There were no differences in rates of graft rejection, leukemia relapse, treatment-related mortality, and disease-free and overall survival rates. At 1 year, 54% and 12% of patients were still on immunosuppression in the IST and TCD cohorts, respectively. TCD was associated with a higher GVHD-free survival at 2 years compared with IST (41% v 19%, respectively; P = .006). CONCLUSION: These results suggest that TCD via CD34 selection might lower long-term morbidity as a result of chronic GVHD without negatively impacting relapse rates in patients with acute myeloid leukemia. Additional prospective studies should be undertaken to definitively address the role of TCD in HCT.
PURPOSE: T-cell depletion (TCD) reduces the incidence of graft-versus-host disease (GVHD) after hematopoietic cell transplantation (HCT). However, concerns about relapse, graft rejection, and variability in technique have limited the widespread application of this approach. PATIENTS AND METHODS: Outcomes of 44 patients receiving HLA-identical sibling TCD grafts using a uniform technique for CD34(+) selection as the sole form of immune suppression were compared with outcomes of 84 patients receiving T-replete grafts and pharmacologic immune suppression therapy (IST). RESULTS: Groups were similar, except for fewer men (36% with TCD v 56% with IST) and more frequent use of radiation-containing regimens (100% with TCD v 50% with IST) in the CD34-selected TCD cohort. The proportion of patients with neutrophil engraftment at day 28 was similar (96% with IST and 100% with TCD grafts). The 100-day rates of grade 2 to 4 acute GVHD were 39% and 23% with IST and TCD grafts, respectively (P = .07). Corresponding 2-year rates of chronic GVHD were lower with TCD grafts than IST (19% v 50%, respectively; P < .001). There were no differences in rates of graft rejection, leukemia relapse, treatment-related mortality, and disease-free and overall survival rates. At 1 year, 54% and 12% of patients were still on immunosuppression in the IST and TCD cohorts, respectively. TCD was associated with a higher GVHD-free survival at 2 years compared with IST (41% v 19%, respectively; P = .006). CONCLUSION: These results suggest that TCD via CD34 selection might lower long-term morbidity as a result of chronic GVHD without negatively impacting relapse rates in patients with acute myeloid leukemia. Additional prospective studies should be undertaken to definitively address the role of TCD in HCT.
Authors: Stephen Couban; David R Simpson; Michael J Barnett; Christopher Bredeson; Lothar Hubesch; Kang Howson-Jan; Tsiporah B Shore; Irwin R Walker; Peter Browett; Hans A Messner; Tony Panzarella; Jeffrey H Lipton Journal: Blood Date: 2002-09-01 Impact factor: 22.113
Authors: R C Barfield; M Otto; J Houston; M Holladay; T Geiger; J Martin; T Leimig; P Gordon; X Chen; R Handgretinger Journal: Cytotherapy Date: 2004 Impact factor: 5.414
Authors: A Schattenberg; T De Witte; F Preijers; J Raemaekers; P Muus; N Van der Lely; J Boezeman; J Wessels; B Van Dijk; J Hoogenhout Journal: Blood Date: 1990-03-15 Impact factor: 22.113
Authors: R Handgretinger; T Klingebiel; P Lang; M Schumm; S Neu; A Geiselhart; P Bader; P G Schlegel; J Greil; D Stachel; R J Herzog; D Niethammer Journal: Bone Marrow Transplant Date: 2001-04 Impact factor: 5.483
Authors: M L Slovak; K J Kopecky; P A Cassileth; D H Harrington; K S Theil; A Mohamed; E Paietta; C L Willman; D R Head; J M Rowe; S J Forman; F R Appelbaum Journal: Blood Date: 2000-12-15 Impact factor: 22.113
Authors: Mary E D Flowers; Pablo M Parker; Laura J Johnston; Alice V B Matos; Barry Storer; William I Bensinger; Rainer Storb; Frederick R Appelbaum; Stephen J Forman; Karl G Blume; Paul J Martin Journal: Blood Date: 2002-07-15 Impact factor: 22.113
Authors: Ahmet H Elmaagacli; Rudolf Peceny; Nina Steckel; Rudolf Trenschel; Hellmut Ottinger; Hans Grosse-Wilde; Ulrich W Schaefer; Dietrich W Beelen Journal: Blood Date: 2002-09-12 Impact factor: 22.113
Authors: Sebastian P Haen; Michael Schumm; Christoph Faul; Lothar Kanz; Wolfgang A Bethge; Wichard Vogel Journal: J Cancer Res Clin Oncol Date: 2015-08-14 Impact factor: 4.553
Authors: Barbara Spitzer; Ann A Jakubowski; Esperanza B Papadopoulos; Kirsten Fuller; Patrick D Hilden; James W Young; Juliet N Barker; Guenther Koehne; Miguel-Angel Perales; Katharine C Hsu; Marcel R van den Brink; Nancy A Kernan; Susan E Prockop; Andromachi Scaradavou; Hugo Castro-Malaspina; Richard J O'Reilly; Farid Boulad Journal: Biol Blood Marrow Transplant Date: 2017-07-12 Impact factor: 5.742
Authors: Nancy Y Villa; Clive H Wasserfall; Amy M Meacham; Elizabeth Wise; Winnie Chan; John R Wingard; Grant McFadden; Christopher R Cogle Journal: Blood Date: 2015-04-22 Impact factor: 22.113
Authors: Pere Barba; Rodrigo Martino; Qin Zhou; Christina Cho; Hugo Castro-Malaspina; Sean Devlin; Albert Esquirol; Sergio Giralt; Ann A Jakubowski; Dolores Caballero; Molly Maloy; Esperanza B Papadopoulos; José Luís Piñana; María Laura Fox; Francisco J Márquez-Malaver; David Valcárcel; Carlos Solano; Lucía López-Corral; Jorge Sierra; Miguel-Angel Perales Journal: Biol Blood Marrow Transplant Date: 2018-01-02 Impact factor: 5.742
Authors: Christopher G Kanakry; Paul V O'Donnell; Terry Furlong; Marcos J de Lima; Wei Wei; Marta Medeot; Marco Mielcarek; Richard E Champlin; Richard J Jones; Peter F Thall; Borje S Andersson; Leo Luznik Journal: J Clin Oncol Date: 2014-09-29 Impact factor: 44.544
Authors: Gunjan L Shah; Michael Scordo; Satyajit Kosuri; Diego Adrianzen Herrera; Christina Cho; Sean M Devlin; Taylor Borrill; Dean C Carlow; Scott T Avecilla; Richard C Meagher; Richard J O'Reilly; Ann A Jakubowski; Esperanza B Papadopoulos; Guenther Koehne; Boglarka Gyurkocza; Hugo Castro-Malaspina; Brian C Shaffer; Miguel-Angel Perales; Sergio A Giralt; Roni Tamari Journal: Biol Blood Marrow Transplant Date: 2017-09-22 Impact factor: 5.742
Authors: S Garciaz; L Castagna; R Bouabdallah; S Fürst; S Bramanti; D Coso; R Crocchiolo; J El-Cheikh; F Broussais; C Chabannon; A Santoro; D Blaise Journal: Bone Marrow Transplant Date: 2015-03-02 Impact factor: 5.483
Authors: Shannon R McCurdy; Yvette L Kasamon; Christopher G Kanakry; Javier Bolaños-Meade; Hua-Ling Tsai; Margaret M Showel; Jennifer A Kanakry; Heather J Symons; Ivana Gojo; B Douglas Smith; Maria P Bettinotti; William H Matsui; Amy E Dezern; Carol Ann Huff; Ivan Borrello; Keith W Pratz; Douglas E Gladstone; Lode J Swinnen; Robert A Brodsky; Mark J Levis; Richard F Ambinder; Ephraim J Fuchs; Gary L Rosner; Richard J Jones; Leo Luznik Journal: Haematologica Date: 2016-10-20 Impact factor: 9.941
Authors: Michael Scordo; Valkal Bhatt; Patrick Hilden; Melody Smith; Katie Thoren; Christina Cho; Gunjan L Shah; Molly A Maloy; Esperanza B Papadopoulos; Ann A Jakubowski; Scott T Avecilla; Richard J O'Reilly; Hugo Castro-Malaspina; Roni Tamari; Brian C Shaffer; Jaap J Boelens; Miguel-Angel Perales; Sergio A Giralt Journal: Biol Blood Marrow Transplant Date: 2019-03-01 Impact factor: 5.742